Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Organogenesis Holdings Inc.NASDAQ: ORGO

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of $104.5M rose 1743.7% year over year, ahead of the +54.1% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +136.4% a year.

Context

  • Accounts receivables amounted to 20.6% of revenue in FY2025, up 14.0 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1743.7% holds above the trailing-twelve-month pace of +54.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$104.5M+303.0% QoQ
Last fiscal yearDec 2025
-$115.8M+264.2% YoY
LTMMar 2026
-$16.97M+54.1% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1743.7%——
1 year+264.2%——
3-year CAGR+136.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(115.8M) USD
Year-over-year change
-264.2%

Accounts Receivables vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +54.1% is the 3rd highest of 8, against a peer median of -75.5%.
  • Accounts receivables amounts to 3.3% of revenue for ORGO, versus a peer median of 2.8%.
ORGO Competitors
Accounts Receivables for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$59.9M USD+225.6%-40.0%8.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$51.06M USD+91.4%+77.2%12.2%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$16.97M USD+54.1%+136.4%3.3%
EOLSEvolus, Inc.LTM Mar 2026$8.53M USD-48.4%+7.0%2.8%
VREXVarex Imaging CorporationLTM Apr 2026$3.7M USD-169.8%—0.4%
BCYCBicycle Therapeutics plcLTM Mar 2026$3.41M USD-86.4%—5.4%
SIGASIGA Technologies, Inc.LTM Mar 2026$2.68M USD-75.5%-22.4%2.9%
ANGOAngioDynamics, Inc.LTM Feb 2026$2.4M USD-146.8%—0.8%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$0 USD———
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ORGO) —-75.5%-7.7%2.8%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income94.9M15.53M4.95M861K37.03M
Depreciation & Amortization16.68M10.73M23.45M17.03M26.94M
Deferred Income Tax(31.98M)1.98M2.01M(10.72M)9.5M
Stock-Based Compensation3.86M6.55M9M10.58M13.3M
Change in Working Capital(39.29M)(34.08M)(18.07M)(48.89M)(132.38M)
Accounts Receivables(30.23M)(8.77M)5.54M(31.8M)(115.8M)
Inventory(9.3M)(9.41M)6.58M(6.2M)(17.92M)
Accounts Payables3.85M3.26M(108K)(2.37M)(528K)
Other Working Capital(3.6M)(19.16M)(30.08M)(8.51M)1.87M
Other Non-Cash Items17.8M24.15M9.59M45.35M35.3M
Operating Cash Flow61.98M24.86M30.92M14.21M(10.31M)
Capital Expenditures(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Debt Repayment(2.01M)(3.01M)(5.17M)(67.64M)(1.17M)
Common Stock Issued2.2M000157K
Common Stock Repurchased000(25.48M)0
Dividends Paid000(1.8M)0
Other Financing Activities(1.22M)814K(332K)1.87M(16.35M)
Financing Cash Flow(1.04M)(2.2M)(5.51M)27.64M(17.36M)
Effect of Forex Changes00000
Net Change in Cash29.72M(11.24M)1.05M31.81M(41.82M)
Free Cash Flow30.76M(9.04M)6.55M4.18M(24.46M)

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.